LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will participate in the 2010 Citi Investment Research Global Healthcare Conference on May 27 at 11:30 a.m. ET. The format of the conference will be a brief presentation and roundtable discussion between management and a Citi investment research analyst followed by a question and answer period from investors in the audience. The conference is being held May 26-27, 2010 in New York City.
A live webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until June 10, 2010.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme® (ferumoxytol) Injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
CONTACT:
AMAG Pharmaceuticals
Carol Miceli, 617-498-3361
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical
MEDIA: